Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Davies, Jessica ^a   Patel, Manali ^b   Gridelli, Cesare ^c   De Marinis, Filippo ^d   Waterkamp, Daniel ^e   McCusker, Margaret E ^e  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c S G MOSCATI HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOMYCIN; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE MARKER; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; REVIEW; SYSTEMATIC REVIEW; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMBINATION DRUG THERAPY; FACTUAL DATABASE; LUNG NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 85017529933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175679     Document Type: Review

References (37)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):ne359-86. https://doi.org/10.1002/ijc.29210 PMID: 25220842
2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute. 2015. http://seer.cancer.gov/csr/1975-2012/.
3. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010. https://doi.org/10.1016/S0140-6736 (14) 62038-9 PMID: 25467588
4. Gupta SK. Role of Crizotinib in previously treated non-small-cell lung cancer. South Asian J Cancer. 2014;3(2):138-40. https://doi.org/10.4103/2278-330X.130468 PMID: 24818111
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8. https://doi.org/10.1056/NEJMoa011954 PMID: 11784875
6. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840-50. https://doi.org/10.1016/S0140-6736 (12) 60919-2 PMID: 23079588
7. Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136:e136-45. https://doi.org/10.1002/ijc.29105 PMID: 25066804
8. Bradley CJ, Dahman B, Given CW. Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid. J Clin Oncol. 2008;26(31):5067-73. https://doi.org/10.1200/JCO.2008.16.3071 PMID: 18794546
9. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28. https://doi.org/10.1093/jnci/djq495 PMID: 21228314
10. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):973-82. https://doi.org/10.1200/JCO.2013.53.1228 PMID: 24567433
11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9. PMID: 19622511
12. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012;65(2):163-78. https://doi.org/10.1016/j.jclinepi.2011.05.008 PMID: 21959223
13. Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2013;13(1):39-43.
14. Bischoff HG, van den Borne B, Pimentel FL, Arellano J, Langer F, Leschinger MI, et al. Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin. 2010;26(6):1461-70. https://doi.org/10.1185/03007991003799180 PMID: 20394472
15. de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, et al; LIFE Study Team. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. Clin Lung Cancer. 2014;15(5):338-45. https://doi.org/10.1016/j.cllc.2014.04.004 PMID: 24925809
16. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, et al; LIFE study team. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol. 2014;140(10):1783-93. https://doi.org/10.1007/s00432-014-1715-2 PMID: 24903964
17. Gridelli C, Ardizzoni A, Barni S, Crinò L, Caprioli A, Piazza E, et al. Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer. 2011;74(3):462-8. https://doi.org/10.1016/j.lungcan. 2011.04.011 PMID: 21592612
18. Moro-Sibilot D, Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, et al. Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin. 2010;26(11):2661-72. https://doi.org/10.1185/03007995.2010.525489 PMID: 20942749
19. Reinmuth N, Payer N, Muley T, Hoffmann H, Herth FJ, Villalobos M, et al. Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. Respir Res. 2013;14:139. https://doi.org/10.1186/1465-9921-14-139 PMID: 24351122
20. Sacher AG, Le LW, Lau A, Earle CC, Leighl NB. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? Cancer. 2015;121(15):2562-9. https://doi.org/10.1002/cncr.29386 PMID: 25891153
21. Carpentier O, Selvaggi L, Jêgu J, Purohit A, Prim N, Velten M, Quoix E. Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study. Clinical lung cancer. 2015 Nov. 30;16(6):496-506. https://doi.org/10.1016/j.cllc. 2015.05.001 PMID: 26071190
22. Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, et al. Second-line therapy for nonsmall cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study. Curr Med Res Opin. 2012;28(8):1253-62. https://doi.org/10.1185/03007995. 2012.703133 PMID: 22697276
23. Younes RN, Pereira JR, Fares AL, Gross JL. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras. 2011;57(6):686-91. PMID: 22249550
24. Zietemann V, Duell T. Every-day clinical practice in patients with advanced non-small-cell lung cancer. Lung Cancer. 2010;68(2):273-7. https://doi.org/10.1016/j.lungcan. 2009.06.023 PMID: 19632737
25. Zietemann V, Duell T. Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer. 2011;73(1):70-7. https://doi.org/10.1016/j.lungcan. 2010.10.017 PMID: 21095039
26. Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015;87(2):176-85. https://doi.org/10.1016/j.lungcan. 2014.11.002 PMID: 25532680
27. Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. Lung Cancer. 2013;82(3):469-76. PMID: 24396885
28. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al; ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2016;27(suppl 5):v1-v27. https://doi.org/10.1093/annonc/mdw326 PMID: 27664245
29. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer. Version 2.2017. www.nccn.org.
30. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461-6. https://doi.org/10.1634/theoncologist.10-7-461 PMID: 16079312
31. Hanna NH. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. Clin Lung Cancer. 2004;5(Suppl 2):S75-9.
32. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-103. https://doi.org/10. 1200/JCO.2000.18.10.2095 PMID: 10811675
33. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32. https://doi.org/10.1056/NEJMoa050753 PMID: 16014882
34. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39. https://doi.org/10.1056/NEJMoa1507643 PMID: 26412456
35. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. https://doi.org/10.1056/NEJMoa1504627 PMID: 26028407
36. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 2013;73(18):2031-51. https://doi.org/10.1007/s40265-013-0142-z PMID: 24288180
37. Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd; 2008. p. 243-96.